Michigan Chronicle
About 90% of liver cancer cases are hepatocellular carcinoma (HCC). The Michigan Chronicle looks at how more African Americans are diagnosed with liver cancer than White Americans. The new TheraBionic P1 medical device that Karmanos will offer patients in 2024 is FDA approved to treat this advanced-stage liver cancer after patients have failed first- and second-line treatment options. Boris Pasche, M.D., Ph.D., FACP, president and CEO at Karmanos, and Anthony Shields, M.D., Ph.D., medical oncologist and leader of the Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team, explain the benefit this new medical device will bring to patients with HCC.
Read the article here.
Boris Pasche, M.D., Ph.D., FACP
Anthony Shields, M.D., Ph.D.